Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 457-464

  Kumagai, Shogo ^a   Marumo, Satoshi ^a   Shoji, Tsuyoshi ^a   Sakuramoto, Minoru ^a   Hirai, Tatsuya ^a   Nishimura, Takafumi ^a   Arima, Nobuyoshi ^a   Fukui, Motonari ^a   Huang, Cheng long ^a  

^a Kitano Hospital   (Japan)

Author keywords

Curative resection; Lung adenocarcinoma; Overall survival; Peripheral monocyte counts; Prognostic factor; Recurrence free survival

Indexed keywords

CD68 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LOG RANK TEST; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; ADENOCARCINOMA; BLOOD; CANCER STAGING; COMORBIDITY; FOLLOW UP; LEUKOCYTE COUNT; LUNG NEOPLASMS; LYMPHOCYTE COUNT; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPHILS; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 84926418714     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.015     Document Type: Article

References (35)

1. Ohtaki Y., Ishii G., Nagai K., Ashimine S., Kuwata T., Hishida T., et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 2010, 5(10):1507-1515.
2. Ito M., Ishii G., Nagai K., Maeda R., Nakano Y., Ohiai A. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest 2012, 142(July (1)):151-158.
3. Srivastava M.K., Andersson A., Zhu L., Harris-White M., Lee J.M., Dubinett S., et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012, 4(3):291-304.
4. Porrata L.F., Ristow K., Colgan J.P., Habermann T.M., Witzig T.H., Inwards D.J., et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012, 97:262-269.
5. Porrata L.F., Ristow K., Habermann T.M., Witzig T.H., Colgan J.P., Inwards D.J., et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol 2012, 157:321-330.
6. Wilcox R.A., Ristow K., Habermann T.M., Inwards D.J., Micallef I.N., Johnston P.B., et al. The absolute peripheral monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012, 53:575-580.
7. von Hohenstaufen K.A., Conconi A., de Campos C.P., Franceschetti S., Bertoni F., Margiotta Casaluci G., et al. Prognostic impact of peripheral monocyte count at presentation in mantle cell lymphoma. Br J Haematol 2013, 162(August (4)):465-473.
8. Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187(February (4)):347-365.
9. World Health Organization Tumours of the lung. Tumours of the lung, pleura, thymus and heart 2004, 10. International Agency for Research on Cancer, Lyon. W.D. Travis, E. Bramvilla, Muller-Hermelink Hk, C.C. Harris (Eds.).
10. Sobin L.H., Gospodarowicz M.K., Wittekind C. International Union Against Cancer (UICC): TNM classification of malignant tumours 2010, John Willkey and Sons Ltd., UK. 7th ed.
11. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
12. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
13. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
14. Siveen K.S., Kuttan G. Role of macrophages in tumour progression. Immunol Lett 2009, 123:97-102.
15. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008, 216:15-24.
16. Kawamura K., Komohara Y., Takaishi K., Katabuchi H., Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009, 59:300-305.
17. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011, 9:216.
18. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
19. Heusinkveld M., de Vos van Steenwijk P.J., Goedemans R., Ramwadhdoebe T.H., Gorter A., Welters M.J., et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011, 187:1157-1165.
20. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J., Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005, 23(35):8959-8967.
21. Dai F., Liu L., Che G., Yu N., Pu Q., Zhang S., et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010, 10:220.
22. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009, 33(1):118-126.
23. Ma J., Liu L., Che G., Yu N., Dai F., You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010, 10:112.
24. Zhang B., Yao G., Zhang Y., Gao J., Yang B., Rao Z., et al. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011, 66(11):1879-1886.
25. Koh Y.W., Kang H.J., Park C., Yoon D.H., Kim S., Suh C., et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012, 17:871-880.
26. Maeda R., Ishii G., Neri S., Aoyagi K., Haga H., Sasaki H., et al. Circulating CD14+CD204+ cells predict postoperative recurrence in non-small-cell lung cancer patients. J Thorac Oncol 2014, 9(2):179-188.
27. Bridges R.B., Wyatt R.J., Rehm S.R. Effect of smoking on peripheral blood leukocytes and serum antiproteases. Eur J Respir Dis Suppl 1985, 139:24-33.
28. Walter R.E., Wilk J.B., Larson M.G., Vasan R.S., Keaney J.F., Lipinska I., et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008, 133(1):19-25.
29. Turner M.C., Chen Y., Krewski D., Calle E.E., Thun M.J. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007, 176(3):285-290.
30. Hoogsteden H.C., van Dongen J.J., van Hal P.T., Delahaye M, Hop W, Hilvering C Phenotype of blood monocytes and alveolar macrophages in interstitial lung disease. Chest 1989, 95(3):574-577.
31. Voltolini L., Bongiolatti S., Luzzi L., Bargagli E., Fossi A., Ghiribelli C., et al. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. Eur J Cardiothorac Surg 2013, 43(1):e17-e23.
32. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995, 13:1221-1230.
33. Teramukai S., Kitano T., Kishida Y., Kawahara M., Kubota K., Komuta K., et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009, 45:1950-1958.
34. O'Dowd C., McRae L.A., McMillan D.C., Kirk A., Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients under going resection for non-small cell lung cancer. J Thorac Oncol 2010, 5:988-992.
35. Kobayashi N., Usui S., Kikuchi S., Goto Y., Sakai M., Onizuka M., et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 2012, 75(2):223-227.